Display options
Share it on

Int J Oncol. 1997 Oct;11(4):835-41. doi: 10.3892/ijo.11.4.835.

Dimethylsilane polyamines, a new class of potential anticancer drugs.

International journal of oncology

N Seiler, F Douaud, R Havouis, N Leroch, J Renault, M Vaultier, J Moulinoux

Affiliations

  1. UNIV RENNES 1,FAC MED,UPRESA CNRS 6027,GRP RECH THERAPEUT ANTICANCEREUSE,INST RECH CANC,F-35043 RENNES,FRANCE. UNIV RENNES 1,FAC PHARM,UMR CNRS 6510,F-35043 RENNES,FRANCE.

PMID: 21528282 DOI: 10.3892/ijo.11.4.835

Abstract

Several members of a new class of structural analogues of the natural polyamines which contain a S1(CH3)(2)- group in the central carbon chain have previously been found to be potent cytostatics to various tumor cell lines. These compounds have been tested with regard to their ability to inhibit the growth of Lewis lung carcinoma grafts in DBA/2 mice. All compounds exerted consistently antitumor effects, however,growth inhibition was only partial at one or two daily doses of 25 mu mol/kg of the drugs. Among the dimethylsilane tetramines only (6-amino-3-azahexyl),(7-amino-4-azaheptyl)-dimethylsilane (AzhexAzhepSi) reduced tumor growth to a significant degree. A major central nervous system pharmacologic effect of the compounds, hypothermia, limitates the administrable amount of the compounds. The dimethylsilane amines have polyamine antagonist properties, and are weak polyamine mimetics, as became obvious from their effect on tumor cells in culture and the present in vivo experiments.

Publication Types